UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-41551 Acrivon Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | ...

Three dose escalation cohorts completed in ACR-2316 Phase 1 trial with tumor shrinkage observed already at dose level (DL)3, below projected recommended Phase 2 dose AACR presentation of ACR-2316 revealing mechanisms underlying its superior preclinical activity with potent mitotic tumor cell death using AP3 Generative Phosphoproteomics Mansoor Raza Mirza, M.D. appointed chief medical officer; accomplished clinician with stellar track record of successfully leading registrational trials through regulatory ap ...

Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose escalation co ...

A downtrend has been apparent in Acrivon Therapeutics, Inc. (ACRV) lately. While the stock has lost 14% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish ...

Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically Phase 1 trial of ACR-2316 ahead of schedule with three dose-escalation cohorts completed; solid tumor shrinkage already observed at dose level three, well below the projected recommended Phase 2 dose WATERTOWN, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “A ...

Acrivon Therapeutics, Inc. (ACRV) has been beaten down lately with too much selling pressure. While the stock has lost 70.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentu ...

Core Insights - Acrivon Therapeutics has appointed Dr. Mansoor Raza Mirza as the new Chief Medical Officer, effective April 9, 2025, succeeding Dr. Jean-Marie Cuillerot [1][2] - Dr. Mirza will lead the clinical development of Acrivon's ongoing trials, including the Phase 2b trial of ACR-368 for endometrial cancer and the Phase 1 study of ACR-2316 [1][2] - Acrivon is focused on precision medicine through its Acrivon Predictive Precision Proteomics (AP3) platform, which aims to match drug candidates to patients based on predicted sensitivity [1][7] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company specializing in precision oncology medicines [7] - The company utilizes its proprietary AP3 platform to discover and develop drug candidates, measuring compound-specific effects on tumor cell protein signaling networks [7][9] - Acrivon's lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial for endometrial cancer [7][8] Clinical Development - ACR-368 has received Fast Track designation from the FDA for its investigation as a monotherapy in endometrial cancer [7] - The ACR-2316 program is also advancing rapidly, showing promising clinical activity during its dose escalation phase [2][8] - Acrivon is developing an OncoSignature test for ACR-368 to identify patients likely to benefit from the treatment, which has received Breakthrough Device designation from the FDA [7] Leadership and Expertise - Dr. Mirza is recognized for his contributions to the clinical development of therapies for ovarian and endometrial cancers, having led multiple successful trials [2][3] - He has authored numerous publications and has been involved in developing national guidelines for managing gynecologic cancers [3][4] - Dr. Mirza's extensive experience includes key positions in various prestigious organizations related to gynecologic oncology [4][5]

Core Viewpoint - Acrivon Therapeutics, Inc. has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates indicate an improvement in the company's underlying business, suggesting potential for stock price appreciation [5][8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7][9]. - Acrivon Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Recent Earnings Estimate Revisions - Acrivon Therapeutics is expected to earn -$2.70 per share for the fiscal year ending December 2025, reflecting a year-over-year change of -13.5% [8]. - Over the past three months, the Zacks Consensus Estimate for Acrivon Therapeutics has increased by 5.8%, indicating positive sentiment among analysts [8].

Core Viewpoint - Acrivon Therapeutics, Inc. (ACRV) has experienced a significant decline of 52.8% over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2]. - ACRV's current RSI reading is 23.16, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium [5]. Group 2: Fundamental Analysis - There is a consensus among sell-side analysts that earnings estimates for ACRV have increased by 4.3% over the last 30 days, which typically correlates with price appreciation [6]. - ACRV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Core Insights - Acrivon Therapeutics is advancing its Generative Phosphoproteomics AP3 platform to enhance drug discovery and development, particularly focusing on endometrial cancer with promising clinical data for its lead candidate ACR-368 [1][3][10] Clinical Developments - ACR-368 demonstrated a confirmed overall response rate (cORR) of 35% in OncoSignature-positive patients with heavily pretreated endometrial cancer, significantly higher than the previous line of therapy's 15% [1][6] - In patients who relapsed after prior anti-PD-1 and chemotherapy, the cORR was 50% with a median duration of response (mDOR) exceeding 10 months, while refractory patients showed a cORR of 33% and mDOR of approximately 3.4 months [1][3][6] - The Phase 1 trial of ACR-2316 is ahead of schedule, with initial clinical activity and tumor shrinkage observed at the third dose level [1][3] Financial Performance - For the fourth quarter and full year ended December 31, 2024, the company reported a net loss of $22.8 million and $80.6 million, respectively, compared to $19.3 million and $60.4 million for the same periods in 2023 [5][7] - Research and development expenses increased to $18.6 million for the quarter and $64.0 million for the full year 2024, primarily due to the ongoing development of ACR-368 and ACR-2316 [7][8] Cash Position - As of December 31, 2024, Acrivon had cash, cash equivalents, and investments totaling $184.6 million, expected to fund operations into 2027 [9][10] Strategic Focus - The company is prioritizing endometrial cancer due to limited treatment options and a compelling commercial opportunity, reallocating resources to ACR-368 and ACR-2316 [1][5][6] - Acrivon is also exploring the potential of ACR-368 in combination with ultra-low dose gemcitabine, with preliminary data suggesting significant sensitization in patients [6][11]